A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Phase 1/2 Unknown
36 enrolled
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Phase 1 Unknown
22 enrolled
CURATE.AI Optimized Modulation for Multiple Myeloma
Phase 2/3 Unknown
20 enrolled
LENDER
Phase 2 Unknown
70 enrolled
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Phase 3 Unknown
406 enrolled
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Phase 3 Unknown
30 enrolled
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Phase 2 Unknown
90 enrolled
KMM1910
Phase 2 Unknown
49 enrolled
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Unknown
300 enrolled
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Phase 2 Unknown
51 enrolled
GEM-CLARIDEX
Phase 3 Unknown
286 enrolled
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Phase 1 Unknown
87 enrolled
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
Phase 3 Unknown
20 enrolled
FiTNEss
Phase 3 Unknown
740 enrolled
IFM2018-01
Phase 2 Unknown
45 enrolled
MUKeleven
Phase 1 Unknown
4 enrolled
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Phase 2 Unknown
25 enrolled
Myeloma XI
Phase 3 Unknown
4,420 enrolled
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
Phase 1/2 Unknown
60 enrolled
MM03
Phase 1/2 Unknown
54 enrolled
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Unknown
50 enrolled